Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0510
-0.0005 (-0.97%)
At close: Apr 28, 2026

PVCT Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-5.43-4.73-3.1-3.55-5.54
Upgrade
Depreciation & Amortization
00.010.010.010.01
Upgrade
Stock-Based Compensation
1.241.28000.02
Upgrade
Other Operating Activities
-0.030.020.050.050.02
Upgrade
Change in Accounts Receivable
-0-00-
Upgrade
Change in Accounts Payable
-0.39-0.57-0.420.810.33
Upgrade
Change in Unearned Revenue
-0.34-0.62-0.56-0.992.5
Upgrade
Change in Other Net Operating Assets
1.621.331.450.621.64
Upgrade
Operating Cash Flow
-3.33-3.28-2.57-3.04-1.01
Upgrade
Short-Term Debt Issued
---1.633.16
Upgrade
Long-Term Debt Issued
2.512.852.48--
Upgrade
Total Debt Issued
2.512.852.481.633.16
Upgrade
Short-Term Debt Repaid
-0.27-0.31-0.28-0.26-0.25
Upgrade
Long-Term Debt Repaid
--0.1---
Upgrade
Total Debt Repaid
-0.27-0.41-0.28-0.26-0.25
Upgrade
Net Debt Issued (Repaid)
2.242.452.191.372.91
Upgrade
Issuance of Common Stock
----0.96
Upgrade
Other Financing Activities
0.850.3--0.15
Upgrade
Financing Cash Flow
3.092.752.191.374.02
Upgrade
Foreign Exchange Rate Adjustments
0-0-0.02-0-0
Upgrade
Net Cash Flow
-0.24-0.54-0.4-1.683.01
Upgrade
Free Cash Flow
-3.33-3.28-2.57-3.04-1.01
Upgrade
Free Cash Flow Margin
-989.56%-532.15%-461.17%-307.52%-
Upgrade
Free Cash Flow Per Share
-0.01-0.01-0.01-0.01-0.00
Upgrade
Cash Interest Paid
00.01---
Upgrade
Levered Free Cash Flow
-1.34-2.93-1.16-0.88-6.94
Upgrade
Unlevered Free Cash Flow
-1.2-2.78-1.03-0.77-6.34
Upgrade
Change in Working Capital
0.890.140.470.454.47
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.